A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Incyte Corporation
Massachusetts General Hospital
Columbia University
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
Abramson Cancer Center at Penn Medicine
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Brown University
Acerta Pharma BV
H. Lee Moffitt Cancer Center and Research Institute
Case Comprehensive Cancer Center
University of Arizona
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
UNC Lineberger Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Stanford University
M.D. Anderson Cancer Center
Cancer Trials Ireland
Masonic Cancer Center, University of Minnesota
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Institute of Hematology & Blood Diseases Hospital, China
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
Thomas Jefferson University
M.D. Anderson Cancer Center
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
Dana-Farber Cancer Institute
Ann & Robert H Lurie Children's Hospital of Chicago
Gruppo Italiano Malattie EMatologiche dell'Adulto
Ann & Robert H Lurie Children's Hospital of Chicago
UNC Lineberger Comprehensive Cancer Center
Pharmacyclics LLC.
Massachusetts General Hospital
Universitätsklinikum Hamburg-Eppendorf
Baylor College of Medicine
Xencor, Inc.
BeiGene
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
OrphAI Therapeutics
St. Jude Children's Research Hospital
Syndax Pharmaceuticals
City of Hope Medical Center
Amgen